Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

HungaryBack to Hungary

Clinical trials in Torokbalint – page 3

69 clinical trials in Torokbalint, Hungary across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Torokbalint at a glance
69
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

69 trials in Torokbalint

Open in trial search

Non-small cell lung cancer stage III+3

Recruiting

Study of Volrustomig and Drug Combination for Patients with Early-stage Resectable Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Non-small cell lung cancer

Recruiting

Study of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Non-small cell lung cancer

Recruiting

Study of Pembrolizumab and V940 for Treating Non-Small Cell Lung Cancer in Patients with Resectable Stage II to IIIB (N2) Not Achieving Complete Response

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer

Recruiting

Study of V940 and Pembrolizumab for Patients with Resected Stage II, IIIA, IIIB Non-Small Cell Lung Cancer

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer

Recruiting

Study to Compare Datopotamab Deruxtecan with Rilvegostomig or Alone Against Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:AstraZeneca AB

Non-small cell lung cancer+2

Recruiting

Study on THIO and Cemiplimab for Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Maia Biotechnology Inc.

K-ras gene mutation+2

Not yet recruiting

Study of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:F. Hoffmann-La Roche AG

Non-small cell lung cancer stage I

Not yet recruiting

Study on Datopotamab Deruxtecan and Rilvegostomig for Stage I Non-Small Cell Lung Cancer Patients with ctDNA-Positive or High-Risk Features

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Non-small cell lung cancer

Not recruiting

Study of Durvalumab and Chemotherapy for Patients with Resectable Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Chronic obstructive pulmonary disease

Not recruiting

Study on the Effectiveness and Safety of Tanimilast for Patients with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Tanimilast
  • Sponsor:Chiesi Farmaceutici S.p.A.

Chronic obstructive pulmonary disease

Not recruiting

Study on the Effectiveness and Safety of CHF6001 DPI with Roflumilast for Patients with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Roflumilast
  • Sponsor:Chiesi Farmaceutici S.p.A.

Chronic obstructive pulmonary disease

Not recruiting

Study on Benralizumab for Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with Frequent Exacerbations

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:AstraZeneca AB

Other cities in Hungary

The busiest research cities in the country

All 71 cities in Hungary

Clinical research in Torokbalint

What the registry says about research in the country

01 Lung Cancer Research

Extensive clinical trials focusing on non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), evaluating innovative combination therapies and immunotherapy approaches.

  • Advanced NSCLC Treatments
  • Stage III-IV Cancer Therapies
  • Immunotherapy Combinations

Multiple studies investigating targeted therapies for various stages of lung cancer, particularly focusing on patients with specific genetic markers and PD-L1 expression levels.

02 Respiratory Conditions

Research initiatives addressing chronic respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD), testing new therapeutic approaches.

  • Uncontrolled Asthma Management
  • COPD Treatment Optimization
  • Cystic Fibrosis Therapies

Studies evaluating novel medications and combination therapies to improve patient outcomes in chronic respiratory conditions.

03 Innovative Therapeutics

Cutting-edge research examining novel drug combinations and treatment approaches, including targeted therapies and immunotherapy agents.

  • Combination Immunotherapies
  • Targeted Molecular Therapies
  • Maintenance Treatment Strategies

Focus on developing personalized treatment approaches based on specific biomarkers and genetic profiles.

Back to HungaryAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.